NantHealth, Inc. (NASDAQ:NH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
On March 28, 2019, the compensation committee of the board of directors of NantHealth, Inc., or the Company, approved the payment of an annual cash bonus of $157,500.07 to Ron Louks, COO, for the year ending December 31, 2018, or Fiscal 2018. In its determination of this cash bonus amount, the compensation committee reviewed the attainment, or partial attainment, of the goals and objectives that had been established for Mr. Louks for Fiscal 2018 which consisted of organizational and financial goals, individual goals, plus a discretionary amount.
On March 28, 2019, the committee also adopted and approved the payment of a cash bonus of $36,250 to Bob Petrou for joining the Company in late 2018 and assisting the Company in its financial reporting and plans since that time. In addition, the committee determined to cease its search for a CFO to replace Mr. Petrou, that Mr. Petrou will serve as the permanent CFO for the Company upon completion of necessary immigration/VISA procedures and, pending such completion, Mr. Petrou will continue to serve as its Interim Principal Accounting Officer/Interim CFO. The committee also adopted and approved an increase to the base salary of Mr. Petrou to $335,000 per year, effective as of March 28, 2019, with a potential cash bonus of up to 50% of his base salary for the year ending December 31, 2019.
About NantHealth, Inc. (NASDAQ:NH)
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.